Introduction {#Sec1}
============

Laminopathies are a group of inherited conditions due to mutations in the *LMNA* gene, that encodes the nuclear envelope proteins lamin A and C, via alternate splicing \[[@CR1]\]. Laminopathies are characterized by a high phenotypic heterogeneity including heart disease, neuromuscular disorders, premature aging and metabolic disorders \[[@CR2]--[@CR5]\]. *LMNA* associated cardiac and skeletal muscle disease - often coexisting in the same patient - are the most frequent clinical manifestations. The spectrum of cardiac involvement ranges from supraventricular tachyarrhythmias and/or conduction system disease to dilated cardiomyopathy (DCM) and ventricular tachyarrhythmias \[[@CR6]--[@CR12]\]. Sudden cardiac death may occur due to bradyarrhythmias or to malignant ventricular arrhythmias \[[@CR13]\], even in the presence of mild left ventricle systolic dysfunction. Similarly, *LMNA*-related neuromuscular disorders are characterized by a wide heterogeneity in clinical manifestations, Emery Dreifuss muscular dystrophy (EDMD) being the most common phenotype. EDMD is typically characterized by early onset joint contractures with slowly progressive scapulo-humero-peroneal muscle weakness, and can be caused by mutations in genes other than *LMNA*, mainly *EMD* that encodes emerin.

Although clinical manifestation in patients with *LMNA* mutations have been extensively described, the exact time course of cardiological and neuromuscular disease and their relation remain unclear. Specifically, it is not known if a neuromuscular onset is associated with a different cardiac phenotype or cardiac disease progression. The aim of this study was therefore to investigate differences in cardiac phenotype and natural history in relation to the presence of neuromuscular involvement at presentation, in patients with a diagnosis of laminopathy. Furthermore, in order to test the hypothesis that neuromuscular presentation (phenotype) per se might be associated with a specific cardiac natural history, irrespective of genetics, we compared patients with neuromuscular presentation and LMNA or EMD mutations.

Methods {#Sec2}
=======

In this observational study, we prospectively evaluated all *LMNA* mutation carriers from a single Italian centre (S.Orsola-Malpighi University Hospital, Bologna), between December 1998 and November 2017. We also retrospectively examined clinical, ECG and echocardiographic reports available prior to evaluation at our centre. According to the presence of signs and/or symptoms of skeletal myopathy at clinical presentation (not necessarily in our centre), patients were divided into two groups: "with neuromuscular onset" and "without neuromuscular onset". Data of 7 patients with *EMD*-related disease were also recorded. All patients underwent periodical clinical, electrocardiographic and echocardiographic monitoring.

DCM was defined as the presence of left ventricular (LV) dilation and systolic dysfunction in the absence of abnormal loading conditions (hypertension or valve disease) or coronary artery disease sufficient to cause global systolic impairment \[[@CR14]\]. "Hypokinetic non-dilated cardiomyopathy" (HNDC) was defined as LV ejection fraction (EF) \< 45% or biventricular global systolic dysfunction in absence of dilatation \[[@CR15]\]. Restrictive cardiomyopathy was defined as a non-dilated LV with normal wall thickness and EF, and severe diastolic dysfunction with restrictive filling pattern, elevated filling pressures and dilated atria \[[@CR14]\]. Sustained ventricular tachyarrhythmias (SVT) were defined as ventricular tachyarrhythmias with a rate ≥ 120/min, lasting \> 30 s.

A neurological involvement was investigated on the basis of personal history and/or symptoms including joint contractures, muscle weakness or wasting, orthopaedic surgery, and exercise tolerance. Electromyography (EMG), muscle imaging or muscle biopsy were performed in selected cases. Patients underwent periodical neurological evaluation, even when no skeletal muscle involvement was recorded at first evaluation. Elevation of serum creatine kinase (CK) in isolation was not considered diagnostic of neuromuscular involvement in absence of clinical, EMG, imaging or histological evidence of skeletal myopathy.

A detailed family history was collected for each proband in order to identify other potentially affected family members. A genetic diagnosis was made by DNA sequencing from peripheral blood and mutations were considered pathogenic if previously described in literature, in the presence of co-segregation or based on the site and the type of mutation. After mutation identification, cascade genetic screening was performed in family members, following informed consent.

Continuous data distribution was assessed with the Shapiro-Wilk test and expressed as median and interquartile range (IQR). Data were compared by the Fisher's exact test for proportions, and Mann Whitney test for continuous variables. Clinical events were reported as counts and percentages (i.e. events/total number of patients × 100). Data were collected following informed consent.

Results {#Sec3}
=======

Of the 41 *LMNA* mutation carriers, 40 were clinically affected. Table [1](#Tab1){ref-type="table"} reports clinical, ECG and echocardiographic characteristics at first evaluation at our centre. Fourteen patients were assigned to the group "with neuromuscular onset" and 26 to the group "without neuromuscular onset". A single *LMNA* mutation carrier, who did not have any cardiac or neuromuscular phenotypic expression at baseline or during follow up, was excluded from the analysis. Table 1Characteristics at first clinical evaluation at our centre of patients with *LMNA* mutations with and without neuromuscular onsetOverallWith neurological OnsetWithout neurological onset*P* valueNumber of patients4014 (35)26 (65)Number of families3112 (39)19 (61)Males22 (55)7 (50)15 (58)0.744Age at symptom onset, yrs33 (21--42)11 (8--30)39 (32--46)\< 0.0001Age at first contact at our center, yrs39 (29--74)31 (20--44)43 (36--49)Follow-up duration, months30 (6--70)24 (12--101)32 (8--63)Diagnostic pathway Signs or symptoms12 (86)19 (73)0.452 Screening2 (14)7 (27)Cardiomyopathy24 (60)5 (36)19 (73)0.040 Dilated CMP13 (32)2 (14)11 (42)0.089 Hypokinetic non dilated CMP8 (20)2 (14)6 (23)0.688 Restrictive CMP2 (5)02 (8)0.533 Right ventricle CMP1 (2)1 (7)00.350History of atrial fibrillation17 (42)6 (43)11 (42)1.000Sinus node dysfunction4 (10)3 (21)1 (4)0.114Atrio-ventricular block23 (57)6 (43)17 (65)0.197 1st degree8 (20)2 (14)6 (23) 2nd degree7 (17)2 (14)5 (19) 3rd degree/high degree8 (20)2 (14)6 (23)Positive familial history for Sudden death7 (17)3 (21)4 (15)0.678 PM implantation (high degree AVB)11 (27)3 (21)8 (30)0.715 CMP16 (40)5 (36)11 (42)0.746NYHA class III- IV7 (17)4 (28)3 (12)0.214PM recipients8 (20)2 (14)6 (23)0.688ICD recipients8 (20)1 (7)7 (27)0.221Values are expressed as N, N (%) or median (interquartile range)*LMNA, EMD* gene codifying for lamin A/C and emerin, respectively, *ICD* implantable cardioverter defibrillator, *PM* pacemaker, *AVB* atrio-ventricular block, *NYHA* New York Heart Association

Patients with neuromuscular onset {#Sec4}
---------------------------------

Among the 14 patients in this group males and females were equally represented. *LMNA* mutations were: 12 missense, 1 splice site, and 1 deletion (Table [2](#Tab2){ref-type="table"}). Median age at first evaluation at our Centre was 31 years (IQR 20--44). The diagnosis of laminopathy occurred following familial screening in 2 patients. At time of genetic diagnosis, overt neuromuscular involvement was present in all cases whereas none had cardiac involvement. Eleven patients (79%) were diagnosed with EDMD in the first or second decade of life and 3 (21%) were diagnosed with a non-specific myopathy in the third decade; median age at diagnosis was 11 years (IQR 8--30). Table 2Genetics of *LMNA* mutated patients with neurological onset (*N* = 14)GeneLocationNucleotide ChangeProtein ChangePredicted Effect**Family 1**F; 16 yoLMNAExon 4c.746G \> Ap.Arg249GlnMissense**Family 2**F; 50 yoLMNAExon 9c.1580G \> Cp.Arg.527.ProMissense**Family 3**M; 38 yoLMNAExon 11c.1930C \> Tp.Arg644CysMissenseM; 38 yoLMNAExon 11c.1930C \> Tp.Arg644CysMissense**Family 4**F; 46 yoLMNAExon 3Exon 4c.569G \> A;c. 746G \> Ap.Arg190Glnp.Arg249GlnMissenseMissense**Family 5**F; 34 yoLMNAExon 1c.203_208 (delAGGTGG)p.Glu68_Val69 delDeletion**Family 6**M; 52 yoLMNAExon 4c.746G \> Ap.Arg249GlnMissense**Family 7**M; 46 yoLMNAExon 9c.1567G \> Ap.Gly523ArgMissense**Family 8**M; 17 yoLMNAExon 4c.775 T \> Gp.Tyr259AspMissense**Family 9**M; 19 yoLMNAExon 4c.746 G \> Ap.Arg249GlnMissense**Family 10**F; 29 yoLMNAIntron 9c.1608 + 1G \> T--Splice site**Family 11**F; 22 yoLMNAExon 1c.188 T \> Ap.Ile63AsnMissenseF; 19 yoLMNAExon 1c.188 T \> Ap.Ile63AsnMissense**Family 12**M; 27 yoLMNAExon 4c.746G \> Ap.Arg249GlnMissense*M* male, *F* female, *yo* years old. The age reported refers to first contact at our centre

Nine patients (64%) developed cardiac involvement prior to referral to our centre (Fig. [1](#Fig1){ref-type="fig"}a summarizes the spectrum of cardiac phenotypic expression). All had rhythm disturbances: 2 (14%) had atrial fibrillation (AF), 1 (7%) atrio-ventricular (A-V) block, 1 (7%) sinus node dysfunction, and 5 (36%) had a combination of brady- and atrial tachyarrhythmias (Fig. [2](#Fig2){ref-type="fig"}). Cardiomyopathy was also present in 5 patients (36%): 2 DCM, 2 HNDC and 1 isolated right ventricular cardiomyopathy mimicking arrhythmogenic right ventricular cardiomyopathy. Patients with LV cardiomyopathy had a severe LV dysfunction (LVEF ≤35%) and 3 had biventricular involvement. Fig. 1**a** Cardiac phenotype spectrum at first clinical evaluation at our centre of patients with *LMNA* mutations and neurological onset (*N* = 14). SSS: sick sinus syndrome; AVB: atrio-ventricular block; CMP: cardiomyopathy; AF atrial fibrillation/flutter. **b** Cardiac phenotype spectrum at first clinical evaluation at our centre of patients with *LMNA* mutations without neurological onset (*N* = 26). SSS: sick sinus syndrome; AVB: atrio-ventricular block; CMP: cardiomyopathy; AF atrial fibrillation/flutter Fig. 2Second degree sino-atrial block with 2:1 conduction ratio in a 22-year old female, with Emery Dreifuss muscular dystrophy due to p.Ile63Asn missense *LMNA* mutation

Two patients (14%) had previously undergone pacemaker (PM) implantation for A-V block, while a single patient had a primary prevention implantable cardiac resynchronization therapy defibrillator (CRT-D). Serum CK levels were raised in 65% of the patients, with a mean abnormal value of 631 UI/L.

Patients without neuromuscular onset {#Sec5}
------------------------------------

Fifteen (58%) of the 26 patients were males, median age at first evaluation at our centre was 43 years (IQR 36--49). Diagnosis was made due to rhythm disturbances or heart failure symptoms in most cases (*n* = 19, 73%). Seven patients (27%) were identified after family screening. *LMNA* mutations were: 16 missense, 7 splice site, 2 deletion and 1 frameshift (Table [3](#Tab3){ref-type="table"}). Table 3Genetics and cardiac manifestations of *LMNA* mutated patients without neurological onset (*N* = 26)GeneLocationNucleotide ChangeProtein ChangePredicted Effect**Family 1**M; 53 yoLMNAExon 6c.1004G \> Ap.Arg335GlnMissenseM; 26 yoLMNAExon 6c.1004G \> Ap.Arg335GlnMissense**Family 2**F; 47 yoLMNAExon 71370delAp.Lys457SerfsX2Deletion**Family 3**M; 19 yoLMNAExon 6c.1003G \> Ap.Arg335GluMissense**Family 4**F; 55 yoLMNAExon 11c.1912G \> Ap.Gly638ArgMissense**Family 5**M; 54 yoLMNAExon 7c.1202G \> Ap.Arg401HisMissense**Family 6**M; 42 yoLMNAExon 1n/ap.Arg72Alafs\*24Frame shift**Family 7**F; 51 yoLMNAExon 4c.752A \> Cp.Gln251ProMissense**Family 8**M; 46 yoLMNAExon 9c.1517 A \> Cp.His506ProMissense**Family 9**F; 38 yoLMNAIntron 9c1608 + 1G \> T--Splice siteM; 35 yoLMNAIntron 9c1608 + 1G \> T--Splice site**Family 10**F; 29 yoLMNAExon 3c.548 T \> Cp.Leu183ProMissense**Family 11**F; 41 yoLMNAExon 6c.1007G \> Ap.Arg336GlnMissense**Family 12**M; 60 yoLMNAIntron 1c.357-1G \> AIVS1-1G \> A--Splice siteF; 46 yoLMNAIntron 1c.357-1G \> AIVS1-1G \> A--Splice siteF; 49 yoLMNAIntron 1c.357-1G \> AIVS1-1G \> A--Splice siteF; 49 yoLMNAIntron 1c.357-1G \> AIVS1-1G \> A--Splice siteM; 21 yoLMNAIntron 1c.357-1G \> AIVS1-1G \> A--Splice site**Family 13**M; 38 yoLMNAExon 6c.1129C \> Tp.Arg377CysMissense**Family 14**M; 50 yoLMNAExon 2c.481G \> Ap.Glu161LysMissense**Family 15**M; 46 yoLMNAExon 2c.466C \> Ap.Arg156SerMissenseM; 34 yoLMNAExon 2c.466C \> Ap.Arg156SerMissense**Family 16**M; 44 yoLMNAExon 4c.671 C \> Tp.Thr224IleMissense**Family 17**F; 39 yoLMNAExon 2c.481G \> Ap.Glu161LysMissense**Family 18**F; 37 yoLMNAExon 2c.513G \> ApLys171AsnMissense**Family 19**F; 36 yoLMNAExon 5c.855delGp.Ala287LeufsX191Deletion*M* male, *F* female, *yo* years old. The age reported refers to first contact at our centre. *n/a* not available

At first clinical evaluation at our centre, 19 patients (73%) had a cardiomyopathy, in isolation (*n* = 3, 11%) or associated with arrhythmias (AF *n* = 5, 19%; A-V block *n* = 6, 23%; both *n* = 5, 19%; Fig. [3](#Fig3){ref-type="fig"}). Seven patients (27%) had arrhythmias in absence of cardiomyopathy: 1 (4%) AF, 5 (19%) A-V block and 1 (4%) a combination of sinus node and A-V node dysfunction. Overall, AF was present in 11 patients (42%). Figure [1](#Fig1){ref-type="fig"}b summarizes the spectrum of cardiac phenotypic expression. Six patients (23%) had previously undergone PM implantation for A-V block and 7 patients (27%) had received a primary prevention implantable cardioverter defibrillator (ICD). Fig. 343-year old male with a *LMNA* frameshift mutation without neuromuscular presentation. **a** V1 lead ECG showing first degree atrio-ventricular block, **b-c** cardiac magnetic resonance showing midwall late gadolinium enhancement in the basal interventricular septum. Suggestive for myocardial fibrosis

Cardiomyopathy phenotype included: 11 DCM, 6 HNDC and 2 restrictive cardiomyopathy. Among the 17 patients with LV systolic dysfunction, 7 (41%) had a severe impairment (LVEF ≤35%), 6 (35%) had biventricular involvement and 3 (17%) had increased LV trabeculations. One 54-year old patient with a history of complete A-V block and AF had a biventricular cardiomyopathy with multiple aneurysms in the diaphragmatic and free wall of the right ventricle. Coronary arteries were unobstructed at angiography. Cardiac magnetic resonance showed a severely dilated left ventricle (indexed end diastolic volume: 146 mL/m2) with systolic dysfunction (EF 40%) and mildly dilated right ventricle (indexed end diastolic volume: 111 ml/m2) with reduced EF (40%) and confirmed the wall motion abnormalities (Fig. [4](#Fig4){ref-type="fig"} a-b). Tissue characterization (Fig. [4](#Fig4){ref-type="fig"} c-d) revealed multiple areas of fibro-fatty replacement. In this case, possible phenocopies including desmosomal-related cardiomyopathy and sarcoidosis were excluded by genetic analysis, positron emission tomography, lung CT and, endomyocardial biopsy. Fig. 4CMR of a 54-year male, carrier of p.Arg401His missense *LMNA* mutation, affected by DCM. (**a-b**) Four chamber and RV long axis SSFP images show biventricular dilation, bulging of the RV free wall (white arrow, panel **a-b**) and diaphragmatic wall (white arrow, panel **b**). (**c**) Two chamber T1-weighted and (**d**) fat suppressed T1-weighted slices showing LV fatty replacement of mid lateral wall (white arrow). (**e**) IR LGE slice showing fibrosis in the infero-lateral wall (with focal transmural pattern) and in the interventricular septum (image quality was due to respiratory artifacts and to the presence of pacemaker \[\*\]). CMR: cardiac magnetic resonance. DCM: dilated cardiomyopathy. SSFP: steady-state free precession. LV-RV: left-right ventricle. IR LGE: inversion recovery late gadolinium enhancement

No patient had evidence of neuromuscular involvement. Serum CK levels were raised in 47% of the patients with a mean abnormal value of 217 UI/L.

Follow-up of patients with neuromuscular onset {#Sec6}
----------------------------------------------

Median follow up was 24 months (IQR 12--101). New onset AF was recorded in 2 patients, therefore 57% experienced atrial tachyarrhythmias by the end of the follow-up. In one patient, the atrial conduction disease progressed to atrial paralysis. Three patients underwent PM implantation for A-V block (*n* = 1), sinus node disease (*n* = 1) or both (*n* = 1). A primary prevention CRT-D was implanted in a patient with new onset HNDC due to positive family history for sudden death, high inducibility of VT on electrophysiological study and moderate LV dysfunction. The patient affected by right ventricular cardiomyopathy received a primary prevention ICD, due to severe right ventricular dysfunction, non-sustained ventricular tachycardias and the need of a pacing for sinus and A-V node dysfunction. Thereafter he experienced an appropriate ICD activation and a progression towards severe biventricular involvement. No sudden death occurred. Five patients with cardiomyopathy had hospital admissions due to heart failure during follow-up and 4 of them subsequently underwent heart transplantation (median age 43 \[IQR 34--48\]).

Follow-up of patients without neuromuscular onset {#Sec7}
-------------------------------------------------

New onset AF was reported in 6 patients (23%) during a median follow up of 32 months (IQR 8--63); 65% of patients had atrial tachyarrhythmias at the end of follow up. With the exception of 2 patients with atrial flutter -- who were treated successfully with cavo-tricuspid isthmus ablation -- the attempts of rhythm control with electrical or pharmacological cardioversion were ineffective. No patients underwent pulmonary vein isolation. Atrial paralysis was documented in a single patient. One patient underwent PM implantation due to A-V block. A primary prevention ICD was implanted in 7 patients (4 new implants and 3 device upgrades) and 1 ICD was implanted for secondary prevention. Four of the ICD recipients (50%) received a CRT-D device. During follow up 6 patients (23%) experienced appropriate shocks and/or antitachycardia pacing for ventricular arrhythmias, with an arrhythmic storm in 3 cases. Six (23%) patients underwent cardiac transplantation (median age 46 \[IQR 34--53\]) due to end stage heart failure (5/6) or to recurrent ventricular arrhythmias (1/6). One patient developed a mild neuromuscular involvement, with muscle atrophy involving the shoulder girdle. Table [4](#Tab4){ref-type="table"} compares clinical events reported during follow-up in the two groups. Table 4Clinical events reported during follow-up in *LMNA* mutated patientsPatients with neurological onset (*N* = 14)Patients without neurological onset (*N* = 26)*P* valueNew onset of atrial fibrillation (any form)2 (14)6 (23)0.688PM implantation3 (21)1 (4)0.114ICD implantation2 (14)8 (31)0.445SVT/arrhythmic storm1 (7)6 (23)0.387Admission for heart failure5 (36)11 (42)0.746Heart transplantation4 (29)6 (23)0.717Thromboembolic events00Values are expressed as N or N (%). *SVT* sustained ventricular tachyarrhythmia, *PM* pacemaker, *ICD* implantable cardioverter defibrillator

Differences in clinical manifestations between patients with and without neuromuscular onset {#Sec8}
--------------------------------------------------------------------------------------------

Patients with neuromuscular onset had an earlier presentation, during infancy or adolescence in most of the cases (median age 11 years), mainly as EDMD, followed by the first evidence of cardiac disease by a median age of 13 years (IQR 10--15) (maximum timelag 38 years). In patients without neuromuscular onset, first cardiac symptoms occurred later in life, at a median age of 39 years (*p* \<  0.0001). Regarding arrhythmias, at the end of the follow-up A-V block (of any degree) and AF had a similar prevalence between the two groups (50% vs 65%, *p* = 0.500 and 57% vs 65%; *p* = 0.735 respectively). Sinus node dysfunction was more frequent in patients with skeletal myopathy (21% vs 4%; *p* = 0.114), whereas atrial paralysis was reported in one patient for each group. Patients with neuromuscular presentation (Fig. [5](#Fig5){ref-type="fig"}) experienced earlier AF (age 28 vs 41, *p* = 0.013) and PM implantation (age 30 vs 44; *p* = 0.086). The percentage of patients requiring permanent pacing (including PM recipients and those who received an ICD due to a concomitant indication for prevention of ventricular arrhythmias) was equal in the two groups (42% vs 42%; *p* = 1.000). Fig. 5Box and whiskers plot showing age distribution of different clinical events in *LMNA* patients with (white) and without (gray) neuromuscular onset. Middle horizontal line inside box indicates median. Bottom and top of the box are 25th and 75th percentiles, the whiskers indicate the lowest and highest value. PM: pacemaker. ICD: implantable cardioverter defibrillator

Patients without neuromuscular presentation had a higher prevalence of cardiomyopathy (73% vs 43%, *p* = 0.089) and were older at diagnosis (age 42 vs 35, *p* = 0.259). DCM was the dominant phenotype in this group (58% of all cardiomyopathies), whereas DCM and HNDC where equally represented in the other group. The higher prevalence of heart muscle involvement in patients without neuromuscular onset was associated with a higher number of implanted ICDs (58% vs 21%, *p* = 0.045) and a higher burden of SVT (23% vs 7%, *p* = 0.387). Despite this, no significant differences were reported in the prevalence of heart transplantation (23% vs 29%; *p* = 0.717) or in the median recipient age (43 vs 46; *p* = 0.593).

All patients with neuromuscular presentation who received a diagnosis of cardiomyopathy had a previous history of rhythm disturbance with the exception of 2 cases, where the diagnosis was concomitant. On the contrary, no pattern of progression from rhythm disturbance to cardiomyopathy was present in those without a neuromuscular presentations: AF and A-V block could precede the diagnosis of cardiomyopathy, be diagnosed at the same time or later. Figure [6](#Fig6){ref-type="fig"} shows the different overall prevalence of clinical events between the two populations. Fig. 6Different overall prevalence at the end of follow-up of clinical events in *LMNA* patients with (white) and without (gray) neuromuscular presentation. AF: atrial fibrillation; PM: pacemaker; CMP: cardiomyopathy; SVT: sustained ventricular tachycardias

Clinical characteristics and follow up of patients with emerinopathy {#Sec9}
--------------------------------------------------------------------

Seven male patients (4 families) affected by X-linked EDMD were referred to our Centre at a median age of 26 years (IQR 14--30) and followed for a median time of 108 months (IQR 72--172). All had neuromuscular symptoms as first evaluation, with a median age of 6 years (IQR 5--8). At last follow up 6 patients (85%) had cardiac involvement. All developed AF at a median age of 27 \[IQR 23--37\]) and 5 required PM implantation at a median age of 23 \[IQR 22--24\] due to A-V block (*n* = 1), sinus node dysfunction (*n* = 1) or both (*n* = 3). A single patient developed cardiomyopathy with mild systolic dysfunction; none had ventricular arrhythmias. The time interval from neurological to cardiac disease onset was of 14,5 years (IQR 14--15). Compared to patients with *LMNA* mutations and a neurological onset, patients with emerinopathy presented a higher burden of AF (85% vs 57%; *p* = 0.337) that occurred an earlier age (27 vs 31 *p* = 0.746), and a higher rate of PM implantation (71 vs 36%; *p* = 0.182) at an earlier age (23 vs 28; *p* = 0.461). Differently, heart muscle involvement was rare (a single case of cardiomyopathy) and no SVT was documented.

Discussion {#Sec10}
==========

The main findings of our study are: 1) neuromuscular onset is a marker for a specific natural history in laminopathy patients. Specifically, these patients have a linear and predictable progression over time, from muscular dystrophy to rhythm disturbances and finally cardiomyopathy. 2) With the exception of sinus node dysfunction, that was more frequent in EDMD patients, the prevalence of A-V block and AF was similar between the two groups, but patients with a neuromuscular presentation had earlier arrhythmias. 3) Prevalence of cardiomyopathy (particularly DCM) and SVT was higher among patients without neuromuscular onset, although the two groups had a similar rate and age of cardiac transplantation.

Most of the patients with neuromuscular presentation (64%) developed cardiac involvement later in life: the delay between neuromuscular and cardiac symptom onset was variable and sometimes very long. These findings suggest that serial reassessment of cardiac status in patients with a diagnosis of EDMD is mandatory. On the other hand, patients without neuromuscular onset did not develop an overt skeletal myopathy (with a single exception). The possibility that these patients could develop neuromuscular involvement in the future cannot however be entirely ruled out due to the limited observation time. Our results are in line with the phenotypic clustering reported by *Benedetti* et al. \[[@CR16]\] in a cohort of patients with *LMNA* mutations, where those with childhood onset had an almost exclusively skeletal muscle involvement (predominantly EDMD), while patients with adult onset developed cardiac disorders or muscle weakness with a limb-girdle distribution. With the limitation of the small size of the screened families in our study population and the limited numbers of relatives who carried the mutation, all the affected relatives of probands with neuromuscular presentation had a skeletal muscle involvement as clinical onset. At the same time, all the affected relatives of patients with an exclusive cardiac phenotype had an isolated cardiological involvement. Differently from our findings, *Bonne* et al. and *Brodsky* et al. \[[@CR17], [@CR18]\] have previously described the possibility of the coexistence of both phenotypes as clinical onset within the same family.

Our data confirm the high frequency of AF in laminopathies, as well as advanced A-V block, requiring PM implantation at a young age. Although the prevalence of high degree A-V block and AF was similar, irrespective of clinical presentation, patients with neuromuscular onset experienced arrhythmia earlier in life (on average AF and PM implantation occurred more than 10 years earlier). On the other hand, sinus node dysfunction was more frequent in patients with EDMD (21% vs 4%). Regarding heart muscle involvement, patients without neuromuscular onset had a prevalence of cardiomyopathy that was almost twice that of the other group (42% vs 73%; *p* = 0.089), mostly DCM. On the contrary DCM and HNDC were equally distributed in patients with neuromuscular presentation. A progression from HNDC to DCM was not observed in this study, suggesting that they could be the expression of two different pathophysiologic models; however, a limited follow-up duration (median 41 months) and heart failure therapy could have masked this progression. We described two cases, 1 in each group, with a cardiac phenotype that mimicked arrhythmogenic cardiomyopathy. *LMNA* carriers have been described with clinical, morphological and histological phenotypes overlapping with arrhythmogenic cardiomyopathy \[[@CR19]\], in the absence of desmosomal gene mutations, with conduction disease being the sole 'red flag' for the correct diagnosis. These findings may justify the need to exclude *LMNA* mutations in patients with suspected arrhythmogenic cardiomyopathy, particularly when conduction disease is present.

This study confirms the malignant nature of laminopathies in terms of ventricular arrhythmias and progression to advanced heart failure. In our series sustained SVTs during the follow-up were more frequent in patients without neuromuscular involvement (23% vs 7%) with just 1 EDMD patient experiencing SVT. The low incidence of events in patients with skeletal myopathy differs from previous reports. *Van Rijsingen* et al. \[[@CR10]\] reported that in patients with *LMNA* mutations, the diagnosis of muscular dystrophy or a positive family history of muscular dystrophy was not associated with a different incidence of ventricular arrhythmias. The rate of SVT reported by the Authors was of 17% in EDMD patients and 19% in non-EDMD patients. More than 20% of the whole population of this study required cardiac transplantation during follow-up and this is consistent with previous reports. *Hasselberg* et al. \[[@CR11]\] reported that 19% of genotyped *LMNA* patients underwent heart transplantation during a follow up of 8 years (median age 46 years). The need for heart transplantation in our series was independent from the involvement of the skeletal muscle and occurred at a median age of 45 years. Differently from what observed for other clinical events, neuromuscular involvement did not lead to an anticipation in the timeline and heart transplant was performed at a similar age in the two groups (median 43 vs 46 years).

In this series, patients with a neuromuscular presentation had a linear predictable progression over time (Fig. [7](#Fig7){ref-type="fig"}). Specifically, skeletal myopathy developed first, followed by arrhythmias (A-V block, sick sinus syndrome and AF in various combinations) and eventually, cardiomyopathy. This pattern of progression was not observed in the other patients. Fig. 7Timeline of clinical events in the lifetime of patients with *LMNA* mutations and neuromuscular onset

The cardiac involvement in X-linked EDMD patients of our study, compared to patients with LMNA mutations and a neurological onset, was characterized by higher burden of supraventricular tachyarrhyrhmias and bradyarrhythmias that occurred at a younger age and a lower frequency of cardiomyopathy.

Limitations {#Sec11}
===========

Referral bias cannot be excluded since this is a study from a single tertiary centre with a cardiac transplant program and expertise for management of complex ventricular tachycardias.

Conclusion {#Sec12}
==========

In patients with laminopathy, the type of disease onset was a marker for a different natural history. Specifically, patients with neuromuscular presentation had an earlier cardiac involvement, characterized by a linear and progressive evolution from rhythm disorders (AF and/or A-V block) to cardiomyopathy. Prevalence of AF and A-V block was similar, regardless of clinical onset, whereas sinus node dysfunction was more frequent in EDMD patients. Patients with neuromuscular onset had a lower prevalence of cardiomyopathy and ventricular arrhythmias, but a similar prevalence of heart transplantation at a similar age.
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